Abstract 3022: ODY-CDK, a brain-penetrant, selective CDK2 inhibitor that demonstrates antitumor activity in an intracranial CCNE1-amplified breast tumor model
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Joe Gozgit, Gerald Lelais, Ellen Vieux, Sam Zelman, Laura Stransky, Hyeseok Shim, Kim Aardalen, Casey Landry, Arun Thottumkara, Jin Choi, Chip Lesburg, Sebastian Schneider, Chaya Stern, Elizabeth McMillan, Hanbin Lu, Caroline Ho, Nigel Waters, John Shen, Natalie Dales, Shifeng Pan, Bob Abraham, Gary D. Glick, Elaine M. Pinheiro
Institution: Odyssey Therapeutics (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409626535